RBC Capital Maintains Outperform on Biogen, Raises Price Target to $242

Benzinga · 07/07 15:38
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $227 to $242.